Methods of diagnosing and treating neurodegenerative diseases
AssigneeThe General Hospital Corporation
InventorsCatherine Cahill, Changning Wang, Jack Rogers
Life of this patent
Estimating the term…
Abstract
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
Claims50
A method for treating an α-synuclein associated disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for treating an α-synuclein associated disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method of treating an α-synuclein associated disease or disorder in a subject, comprising administering to a subject identified or diagnosed as having an α-synuclein associated disease or disorder a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method of treating an α-synuclein associated disease or disorder in a subject, comprising administering to a subject identified or diagnosed as having an α-synuclein associated disease or disorder a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method of treating an α-synuclein associated disease or disorder in a subject, comprising:
- determining that the disease or disorder in the subject is an α-synuclein associated disease or disorder;
- and administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method of treating an α-synuclein associated disease or disorder in a subject, comprising:
- determining that the disease or disorder in the subject is an α-synuclein associated disease or disorder;
- and administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method of treating a subject, comprising administering a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing, to a subject having a clinical record that indicates that the subject has an α-synuclein associated disease or disorder.
A method of treating a subject, comprising administering a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing, to a subject having a clinical record that indicates that the subject has an α-synuclein associated disease or disorder.
A method for inhibiting α-synuclein translation in a mammalian cell, comprising contacting the mammalian cell with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for inhibiting α-synuclein translation in a mammalian cell, comprising contacting the mammalian cell with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for inhibiting Lewy body formation in mammalian brain tissue, comprising contacting the mammalian brain tissue with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for inhibiting Lewy body formation in mammalian brain tissue, comprising contacting the mammalian brain tissue with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A pharmaceutical composition comprising a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.
A pharmaceutical composition comprising a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.
A method for detecting an α-synuclein associated disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method for detecting an α-synuclein associated disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method of detecting an α-synuclein associated disease or disorder in a subject, comprising administering to a subject suspected as having an α-synuclein associated disease or disorder an effective amount a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method of detecting an α-synuclein associated disease or disorder in a subject, comprising administering to a subject suspected as having an α-synuclein associated disease or disorder an effective amount a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method for detecting α-synuclein translation in a mammalian cell, comprising contacting the mammalian cell with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method for detecting α-synuclein translation in a mammalian cell, comprising contacting the mammalian cell with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method for detecting Lewy body formation in mammalian brain tissue, comprising contacting the mammalian brain tissue with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
A method for detecting Lewy body formation in mammalian brain tissue, comprising contacting the mammalian brain tissue with an effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
An imaging composition comprising a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
An imaging composition comprising a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients;
- wherein the compound, or a pharmaceutically acceptable salt thereof, is radiolabeled.
Dependencies are inferred from the claim text.